Biogen Available for sale investments increased by 10.2% to $1.37B in Q1 2026 compared to the prior quarter. Over 3 years (FY 2020 to FY 2025), Available for sale investments shows a downward trend with a -15.5% CAGR.
An increase suggests higher liquidity and potential for capital gains, while a decrease may indicate asset liquidation or market value depreciation.
This represents the fair value of debt securities that are not classified as held-to-maturity or trading. These assets a...
Standard across insurance and banking sectors as part of the investment portfolio.
other_available_for_sale_securities_debt_securities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.22B | $2.38B | $2.43B | $3.00B | $3.25B | $2.10B | $2.18B | $3.12B | $4.67B | $97.60M | $1.24B | $1.37B |
| QoQ Change | — | +7.1% | +2.2% | +23.5% | +8.3% | -35.6% | +4.0% | +43.2% | +49.6% | -97.9% | >999% | +10.2% |
| YoY Change | — | — | — | — | +46.3% | -12.0% | -10.4% | +3.9% | +43.5% | — | — | — |